Physician profile
Mark E Weinstein
NPI 1528274040
$88,282.16
in general payments reported to CMS, 2019-2025
41 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $6,564 · 2021: $8,173 · 2022: $13K · 2023: $15K · 2024: $4,715 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $3,397 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,409.25 |
| Food and Beverage | $3,396.70 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37,990.75 | 2020-2025 | Takhzyro, Cinryze, Cuvitru |
| Abbvie INC. | $18,935.56 | 2022-2025 | Rinvoq |
| Genzyme Corporation | $13,514.34 | 2019-2025 | |
| Shire North American Group INC | $10,112.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,263.24 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,189.36 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $996.06 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $846.89 | 2019-2025 | Hizentra, Haegarda |
| Pfizer INC. | $528.56 | 2019-2025 | |
| Pharming Healthcare, INC. | $285.39 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $263.76 | 2019-2025 | |
| Amgen INC. | $245.68 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $239.89 | 2019-2024 | Xolair |
| Covis Pharma Gmbh | $221.86 | 2019-2022 | |
| Kaleo, INC. | $168.23 | 2019-2024 | Auvi-Q |
Show all 38 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.